Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

News

Pharmacy wars: Sigma tops Wesfarmers bid for API

Emma Rapaport  |  29 Sep 2021Text size  Decrease  Increase  |  
Email to Friend

Morningstar analysts say Sigma's proposed acquisition of Priceline owner Australian Pharmaceutical Industries faces significant hurdles and will likely attract resistance from the competition watchdog.

In a research note, Shane Ponraj estimates the market share of a merged Sigma/API entity would be roughly half of Australia's pharmacy distribution network, ringing alarm bells at the Australian Competition and Consumer Commission's (ACCC) who blocked a similar deal two decades ago.

Sigma's (ASX: SIG) network of 1,200 stores includes brands Amcal, Guardian and PharmaSave while API's (ASX: API) brands include Priceline and Priceline Pharmacy franchises and the Clear Skincare network.

"The ACCC prevented a Sigma API merger in 2002 as it would have commanded over 60% of the pharmaceutical wholesaling market in Australia's eastern states and over 50% in others," he says.

"Since 2002, Sigma has lost a material Chemist Warehouse contract to EBOS Healthcare, and competitors DHL Pharmacy Supply and Clifford Hallam Healthcare have a greater presence in the space."

"However, we still estimate that the current market share of a merged entity would be roughly 50% of Australia's pharmacy distribution.

"As such, there is considerable risk of ACCC resistance to the deal."

Investing Compass
Listen to Morningstar Australia's Investing Compass podcast
Take a deep dive into investing concepts, with practical explanations to help you invest confidently.
Investing Compass

Sigma Healthcare jumped into the race for API on Monday, outbidding Wesfarmers (ASX: WES) by a small premium.

The pharmacy group made a nonbinding offer to acquire no-moat API for 35 cents in cash and $2.05 Sigma shares per API share, implying a $1.57 consideration (based on Sigma's closing price on 24 September 2021). The API board has since deemed it superior to Wesfarmers' September 16 bid of $1.55 cash per share and allowed Sigma to undertake due diligence in parallel with Wesfarmers.

Wesfarmers had initially bid $1.38 cash per cash in July. At the time, Morningstar analyst Johannes Faul described the bid as "opportunistic", coming as lockdown restrictions led to the temporary closure of 75% of Clear Skincare clinic and about one-fifth of Priceline's network.

Ponraj says Sigma's API bid could struggle to gain necessary approval given Wesfarmers' capacity to block to deal in the event of lower shareholder turnout.

"Wesfarmers made an agreement with Washington H. Soul Pattinson that if its bid was to go to a shareholder vote, WSP would vote in favour. WSP has a 19% ownership in API. In the event of a competing offer, Wesfarmers would have the option to acquire WSP's holding.”

"For a successful bid, Sigma must secure at least a 75% 'yes' vote from API shareholders. However, not all shareholders need to be present for the vote, as long as half are represented.

"It's unlikely all the shareholders would attend the vote. If 80% turn up, this would allow Wesfarmers to block the acquisition using its 19% interest from WSP."

Cost savings

This is far from the first time Sigma has attempted to acquire API. Bids were made in 2002 and 2006, the former failing due to competitive concerns and the latter on valuation. API sought to acquire Sigma in 2018.

Ponraj says a Sigma/API tie-up would offer the merged entity greater buying power to negotiate terms from drug manufacturers and allow it to find efficiencies in its logistics operations.

Sigma estimates $45 million in potential cost synergies but Ponraj says there are risks in its ability to execute in full. 

Morningstar's Faul says a Wesfarmers/API deal is "far from transformational" for the conglomerate due to the relatively small size of API – $0.8 billion compared to WES' market capitalisation of over $65 billion.

"The potential addition of no-moat API to the conglomerate's stable is too immaterial to impact Wesfarmers' competitive advantage," he says.

"The balance sheet is capable of much larges moves, which could have the potential to add greater value for shareholders."

Since Coles demerged from Wesfarmers' in 2018, management has overseen several smaller acquisitions including Catch Group, Kidman Resources and Geeks2U.

Morningstar is maintaining its $1.55 fair value for API, $0.69 fair value for Sigma and $39.50 fair value for Wesfarmers. 

is the editorial manager for Morningstar Australia. Connect with Emma on Twitter @rap_reports. You can email Morningstar's editorial team editorialAU[at]morningstar[dot]com

© 2021 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Any general advice or 'regulated financial advice' under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information, refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ). Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar’s full research reports are the source of any Morningstar Ratings and are available from Morningstar or your adviser. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a licensed financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782. The article is current as at date of publication.

Email To Friend